Updates from the central pathology review in patients with advanced stage mycosis fungoides (MF) and Sezary syndrome (SS) for the Global PROCLIPI study

2018 ◽  
Vol 101 ◽  
pp. S16-S17
Author(s):  
Alejandro Gru ◽  
Maxime Battistella ◽  
Melissa Pulitzer ◽  
Joya Pawade ◽  
Helmut Beltraminelli ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage ◽  
Central Pathology ◽  
Pathology Review

The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome

2018 ◽  
Vol 42 (6) ◽  
pp. 726-734 ◽  
Author(s):  
Alejandro A. Gru ◽  
Jinah Kim ◽  
Melissa Pulitzer ◽  
Joan Guitart ◽  
Maxime Battistella ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage ◽  
Digital Slide ◽  
Central Pathology ◽  
Pathology Review

Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome

2018 ◽  
Vol 20 (4) ◽  
Author(s):  
Louise Photiou ◽  
Carrie van der Weyden ◽  
Christopher McCormack ◽  
H. Miles Prince
Keyword(s):  
Mycosis Fungoides ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage

Safety and outcome of allogeneic stem cell transplantation in mycosis fungoides and Sezary syndrome: A seven-year tertiary center analysis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e20038-e20038
Author(s):  
Selami Kocak Toprak ◽  
Guldane Cengiz Seval ◽  
Erden Atilla ◽  
Sinem Civriz Bozdag ◽  
Meltem Kurt Yuksel ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Mycosis Fungoides ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage ◽  
Hematopoietic Stem ◽  
Tertiary Center ◽  
Unrelated Donors

e20038 Background: Allogeneic hematopoietic stem cell transplantation (AHSCT) is a promising strategy for treatment of advanced-stage mycosis fungoides/Sezary syndrome (MF/SS). In this study, we retrospectively analyzed the outcomes of AHSCT for MF/SS and found that MF/SS appears to be susceptible to graft versus leukemia (GVL) effects. Methods: We studied outcomes in a consecutive series of 14 patients with MM/SS who underwent AHSCT between January 2012-November 2019 at our center. Treatment response was evaluated according to the Consensus WHO criteria for MF/SS. Results: The median age of patients 51.5 years (range: 28-68 years). Eight patients had MF and six patients had SS. Nine of those 14 patients had large cell transformation. All patients had advanced disease (stages IIB: n = 1, IIIA: n = 2, IIIB: n = 6, IVA1: n = 2 and IVB = 3). The median interval from disease onset to AHSCT was 3.7 years (range: 10.5 mos-11.3 years). All of the patients received at least three lines of treatments prior to AHSCT. Four patients achieved CR (3 are alive and still in CR) and all the other patients had progressive disease (PD) at the time of AHSCT. Graft source was peripheral blood stem cell in all patients. Six patients underwent transplantation from 9/10 HLA-matched unrelated donors and eight patients from HLA-identical sibling donors. Most of the patients (12/14) received RIC regimen (Flu-Cy-TBI) and ATG-Fresenius also added the protocol in AHSCT from unrelated donors. Five patients had stage 2-4 cutaneous acute GVHD and chronic GVHD developed in four patients (mild: n = 1, moderate: n = 2, severe: n = 1). Six patients who underwent transplantation at PD attained CR after AHSCT however relapse occurred in four patients at a median of four months (range: 3-10 months) after HSCT. At the time of data collection, nine patients have deceased; three were due to early TRM, three were underlying disease, two had aspergillus infection and one had nocardia infection. Two patients were alive with disease being treated by the Brentixumab vedotin, gemcitabine and DLI. With a median follow up period of 8.7 months after AHSCT, the estimated 1-year OS and PFS was 40.4%±5% and 35.4%±3.9%, respectively. Conclusions: AHSCT is an effective treatment option for advanced-stage MF/SS. Further studies are warranted to improve the outcome after AHSCT.

scholarly journals Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome

2012 ◽  
Vol 39 (5) ◽  
pp. 500-507 ◽  
Author(s):  
Meghali Goswami ◽  
Madeleine Duvic ◽  
Alexis Dougherty ◽  
Xiao Ni
Keyword(s):  
Mycosis Fungoides ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage ◽  
Twist Expression

Advanced-Stage Mycosis Fungoides and Sézary Syndrome: Survival and Response to Treatment

2015 ◽  
Vol 15 (6) ◽  
pp. e105-e112 ◽  
Author(s):  
Silvia Alberti-Violetti ◽  
Rakhshandra Talpur ◽  
Megan Schlichte ◽  
Dawen Sui ◽  
Madeleine Duvic
Keyword(s):  
Mycosis Fungoides ◽  
Response To Treatment ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage
Sign in / Sign up

Export Citation Format

Share Document